Literature DB >> 15711258

Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE.

Christopher J Kane1, William W Bassett, Natalia Sadetsky, Stefanie Silva, Katrine Wallace, David J Pasta, Matthew R Cooperberg, June M Chan, Peter R Carroll.   

Abstract

PURPOSE: We investigated the association of obesity with prostate cancer case demographics and clinical disease features at presentation.
MATERIALS AND METHODS: Data were abstracted from CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor), a disease registry of 10,018 men with prostate cancer. A total of 2,952 men were included who were treated between 1989 and 2002, and had complete body mass index (BMI) information. BMI classes were defined as normal (less than 25 kg/m), overweight (25 to 29.9 kg/m), obese (30 to 34.9 kg/m) or very obese (35 kg/m or greater). Patients were categorized as having low, intermediate or high risk disease based on the D'Amico classification. Associations among BMI, risk and demographics were analyzed using univariate and multivariate models.
RESULTS: Of the patients 29% had a normal BMI, 51% were overweight, 16% were obese and 5% were very obese. Patients who were overweight or obese were more likely to be young, have hypertension and diabetes, and have a lower education level. The overweight group had a lower serum prostate specific antigen (p = 0.010) and lower stage disease (p = 0.030) at diagnosis, but there was no association between Gleason score and obesity (p = 0.57). However, among men with a BMI of 25 kg/m or greater there was a positive correlation between increasing BMI and risk of being in a worse prognostic group at diagnosis (p = 0.018).
CONCLUSIONS: Overweight and obese patients are more likely to be young at diagnosis and have multiple comorbidities. Men in the overweight and obese groups presented with lower risk prostate cancer at diagnosis. This may be due to earlier disease detection secondary to more frequent interaction with the medical community. Among overweight and obese patients increased obesity is associated with a slightly increased chance of having high risk prostate cancer at diagnosis.

Entities:  

Mesh:

Year:  2005        PMID: 15711258     DOI: 10.1097/01.ju.0000152408.25738.23

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Screening for prostate cancer using multivariate mixed-effects models.

Authors:  Christopher H Morrell; Larry J Brant; Shan Sheng; E Jeffrey Metter
Journal:  J Appl Stat       Date:  2012-06-01       Impact factor: 1.404

2.  Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

3.  Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy.

Authors:  Crystal S Langlais; Janet E Cowan; John Neuhaus; Stacey A Kenfield; Erin L Van Blarigan; Jeanette M Broering; Matthew R Cooperberg; Peter Carroll; June M Chan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-28       Impact factor: 4.254

Review 4.  Diet and prostate cancer prevention.

Authors:  James R Marshall
Journal:  World J Urol       Date:  2012-01-17       Impact factor: 4.226

5.  Dietary n-3 polyunsaturated fatty acids fail to reduce prostate tumorigenesis in the PB-ErbB-2 x Pten(+/-) preclinical mouse model.

Authors:  Sarada Vissapragada; Anup Ghosh; Lymor Ringer; Patricia Salinas; Amanda Brophy; Daniel Peaceman; Bhaskar Kallakury; Partha P Banerjee; Stanley T Fricke; William Helfrich; Yi Chien Lee; Richard Pestell; Philipp Scherer; Herbert B Tanowitz; Maria Laura Avantaggiati; Leena Hilakivi-Clarke; Michael P Lisanti; Olga C Rodriguez; Chris Albanese
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

Review 6.  Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?

Authors:  Piotr Zareba; Wilhelmina Duivenvoorden; Darryl P Leong; Jehonathan H Pinthus
Journal:  Ther Adv Urol       Date:  2015-11-30

7.  Associations of body mass index, smoking, and alcohol consumption with prostate cancer mortality in the Asia Cohort Consortium.

Authors:  Jay H Fowke; Dale F McLerran; Prakash C Gupta; Jiang He; Xiao-Ou Shu; Kunnambath Ramadas; Shoichiro Tsugane; Manami Inoue; Akiko Tamakoshi; Woon-Puay Koh; Yoshikazu Nishino; Ichiro Tsuji; Kotaro Ozasa; Jian-Min Yuan; Hideo Tanaka; Yoon-Ok Ahn; Chien-Jen Chen; Yumi Sugawara; Keun-Young Yoo; Habibul Ahsan; Wen-Harn Pan; Mangesh Pednekar; Dongfeng Gu; Yong-Bing Xiang; Catherine Sauvaget; Norie Sawada; Renwei Wang; Masako Kakizaki; Yasutake Tomata; Waka Ohishi; Lesley M Butler; Isao Oze; Dong-Hyun Kim; San-Lin You; Sue K Park; Faruque Parvez; Shao-Yuan Chuang; Yu Chen; Jung Eun Lee; Eric Grant; Betsy Rolland; Mark Thornquist; Ziding Feng; Wei Zheng; Paolo Boffetta; Rashmi Sinha; Daehee Kang; John D Potter
Journal:  Am J Epidemiol       Date:  2015-08-04       Impact factor: 4.897

8.  Impact of obesity on functional and oncological outcomes in radical perineal prostatectomy.

Authors:  Bulent Altay; Bulent Erkurt; Vahit Guzelburc; Murat Can Kiremit; Mustafa Yucel Boz; Selami Albayrak
Journal:  Can Urol Assoc J       Date:  2015-11-04       Impact factor: 1.862

Review 9.  Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer.

Authors:  Handoo Rhee; Ian Vela; Eric Chung
Journal:  Horm Cancer       Date:  2015-11-06       Impact factor: 3.869

10.  Periprostatic fat measured on computed tomography as a marker for prostate cancer aggressiveness.

Authors:  Joep G H van Roermund; Gijsbert H Bol; J Alfred Witjes; J L H Ruud Bosch; Lambertus A Kiemeney; Marco van Vulpen
Journal:  World J Urol       Date:  2009-12-22       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.